VIVUS Press Releases

Date Title Links
Toggle Summary VIVUS to Host Second Quarter Business Update and Financial Results Conference Call on Tuesday, August 6, 2019
CAMPBELL, Calif. , July 23, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the second quarter of 2019 after the market close on Tuesday, August 6, 2019 . The company will host a conference call beginning at
View HTML
Toggle Summary VIVUS and Nordmark Amend Contract Manufacturing Agreement to Supply Current and Future Demand for PANCREAZE®
-Companies will also collaborate to develop additional PANCREAZE dose formulations and an advanced formulation with an extended shelf life- CAMPBELL, Calif. , June 26, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (“VIVUS”), a biopharmaceutical company, today announced an amendment to its
View HTML
Toggle Summary VIVUS Reduces Barrier to Achieving Healthy Weight Goals With Launch of Online Platform to Purchase Qsymia®
A 30% plus reduction in patient out of pocket expense for medication, on-line purchasing and direct home delivery better enable patients to initiate and maintain Qsymia therapy CAMPBELL, Calif. , June 11, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical
View HTML
Toggle Summary VIVUS Initiates Phase Four Safety and Efficacy Study of Qsymia® in Obese Adolescents
                -Post-marketing study designed to evaluate Qsymia as an approach to weight management in a growing patient population with significant unmet medical need- CAMPBELL, Calif. , May 28, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company,
View HTML
Toggle Summary VIVUS Partners with HarborPath Direct to Facilitate Access to PANCREAZE® for Patients Without Health Insurance
CAMPBELL, Calif. and CHARLOTTE, N.C., May 15, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, and HarborPath Direct, Inc. , today announced a partnership to facilitate access to PANCREAZE ® (pancrelipase) Delayed Release Capsules for uninsured or
View HTML
Toggle Summary VIVUS Reports First Quarter 2019 Financial Results
Company to host conference call today at 4:30pm ET CAMPBELL, Calif. , April 30, 2019 (GLOBE NEWSWIRE) -- VIVUS , Inc. (NASDAQ: VVUS) (the "Company"), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients
View HTML
Toggle Summary VIVUS to Host First Quarter Business Update and Financial Results Conference Call on Tuesday, April 30, 2019
CAMPBELL, Calif. , April 16, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the first quarter of 2019 after the market close on Tuesday, April 30, 2019 . The company will host a conference call beginning at
View HTML
Toggle Summary VIVUS Announces Marketing Approval of Avanafil in the Russian Federation for the Treatment of Erectile Dysfunction
March 14, 2019 (ACCESSWIRE via COMTEX) -- CAMPBELL, CA / ACCESSWIRE / March 14, 2019 / VIVUS, Inc. VVUS, -1.41% a biopharmaceutical company, today announced that the Ministry of Health of the Russian Federation has approved 50 mg, 100 mg and 200 mg tablets of avanafil for the treatment of erectile
View HTML
Toggle Summary VIVUS Reports Fourth Quarter 2018 Financial Results
Company to host conference call today at 4:30pm ET CAMPBELL, Calif. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- VIVUS , Inc. (NASDAQ: VVUS) (the "Company"), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with
View HTML
Toggle Summary VIVUS to Host Fourth Quarter and Full Year Business Update and Financial Results Conference Call on Tuesday, February 26, 2019
CAMPBELL, Calif. , Feb. 13, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the fourth quarter and full year of 2018 after the market close on Tuesday, February 26, 2019 .
View HTML